索拉尼祖马布再次失败 - 这一次是在临床前阿尔茨海默病的阿尔茨海默病中
1School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia.
Expert opinion on biological therapy
|February 28, 2024
概括
抗粉样蛋白抗体Solanezumab未能减缓临床前阿尔茨海默病的认知衰退. 对类似阿尔茨海默氏症治疗的进一步试验需要更现实的评估.
科学领域:
- 神经学 神经学
- 免疫治疗是一种免疫疗法.
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 是导致死亡的主要原因,没有治愈.
- 目前的治疗方法,如lecanemab显示边际有效性.
- 索拉尼祖马布是一种针对阿尔茨海默氏症进行研究的抗粉样性单克隆抗体.
研究的目的:
- 在临床前阿尔茨海默病的第三阶段临床试验中评估solanezumab的疗效.
- 评估solanezumab对认知和功能衰退的影响.
- 为了确定solanezumab对大脑粉样蛋白负担的影响.
主要方法:
- 3期临床试验 (A4研究) 涉及solanezumab.
- 评估参与者的认知和功能衰退.
- 测量大脑粉样蛋白负担.
主要成果:
- 索拉尼祖马布并没有显著降低认知能力下降.
- 索拉尼祖马布并没有显著减少功能衰退.
- 没有观察到solanezumab对大脑粉样蛋白负担的影响.
结论:
- A4试验表明,solanezumab在临床前AD中没有益处.
- 鉴于之前的试验失败,solanezumab的开发应该重新考虑.
- 未来的抗粉样抗体试验需要更加谨慎和现实的计划.
相关概念视频
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
01:26Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481